Primary study · included by 1 review

Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial.

Lynggaard 2022 (MESRIX 12-month follow-up) · Lynggaard Charlotte Duch, Grønhøj Christian, Jensen Siri B, et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · 2022

Included by

Treatment of Xerostomia with Mesenchymal Stem Cells - A Systematic Review and Meta-Analysis of Clinical Trials.

Non-Cochrane · intervention · 2026 · cited as Lynggaard 2022 (MESRIX 12-month follow-up) · Results, Table 1; reference 34; ROB-ME supplement

Outcome this study informs	Pooled effect	Evidence	Certainty
Unstimulated whole salivary flow rate (UWS) Mesenchymal stem cell (MSC) injection into the salivary glands vs Placebo (saline, saline with albumin, or DMSO) · Long term (6 months to 2 years; latest time point, 12 months)	MD 0.01 [-0.02, 0.05]	2 studies · 150 participants	GRADE not reported

1 including review in total.